Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Business News, In Brief

Executive Summary

Pfizer Lays Out Primary Care Business Development Opportunities

You may also be interested in...



As More Indian Companies Dive Into Biosimilars, Will Success In Generic Drugs Repeat?

MUMBAI - In August, when leading Indian drug maker Dr. Reddy's Labs launched Cresp, a biosimilar brand of Amgen's darbepoetin alfa Aranesp, G.V.Prasad, Reddy's chief executive officer exulted at a media briefing that his company may well be on course to becoming the largest biologics player in the world in a few years, next only to Swiss giant Roche

Merck And Teva Settle Temodar Patent Suit, But Appeals Case Continues

Teva will launch its generic only if an appeals court finds the Temodar patent is unenforceable; otherwise it can do so six months before the patent expires.

Merck Pumps Pipeline With $800M Cardiome Deal

FDA-delayed vernakalant for atrial fibrillation nets handsome pact, as more-lucrative oral form awaits Phase III trials.

Topics

UsernamePublicRestriction

Register

OM004674

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel